50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,706.77 (+1.63%)
DOW   29,582.77 (+1.54%)
QQQ   277.85 (+1.23%)
AAPL   147.18 (-3.02%)
MSFT   239.77 (+1.42%)
META   139.66 (+3.91%)
GOOGL   99.63 (+2.18%)
AMZN   116.93 (+2.20%)
TSLA   283.05 (+0.04%)
NVDA   127.24 (+2.51%)
NIO   17.19 (+0.00%)
BABA   80.38 (+3.22%)
AMD   68.52 (+2.01%)
T   15.83 (+0.64%)
MU   50.56 (-0.04%)
CGC   3.00 (+4.90%)
F   12.12 (+1.76%)
GE   64.77 (+0.47%)
DIS   98.76 (+3.04%)
AMC   7.58 (+1.74%)
PYPL   89.01 (+3.80%)
PFE   44.45 (+0.82%)
NFLX   240.32 (+7.11%)
S&P 500   3,706.77 (+1.63%)
DOW   29,582.77 (+1.54%)
QQQ   277.85 (+1.23%)
AAPL   147.18 (-3.02%)
MSFT   239.77 (+1.42%)
META   139.66 (+3.91%)
GOOGL   99.63 (+2.18%)
AMZN   116.93 (+2.20%)
TSLA   283.05 (+0.04%)
NVDA   127.24 (+2.51%)
NIO   17.19 (+0.00%)
BABA   80.38 (+3.22%)
AMD   68.52 (+2.01%)
T   15.83 (+0.64%)
MU   50.56 (-0.04%)
CGC   3.00 (+4.90%)
F   12.12 (+1.76%)
GE   64.77 (+0.47%)
DIS   98.76 (+3.04%)
AMC   7.58 (+1.74%)
PYPL   89.01 (+3.80%)
PFE   44.45 (+0.82%)
NFLX   240.32 (+7.11%)
S&P 500   3,706.77 (+1.63%)
DOW   29,582.77 (+1.54%)
QQQ   277.85 (+1.23%)
AAPL   147.18 (-3.02%)
MSFT   239.77 (+1.42%)
META   139.66 (+3.91%)
GOOGL   99.63 (+2.18%)
AMZN   116.93 (+2.20%)
TSLA   283.05 (+0.04%)
NVDA   127.24 (+2.51%)
NIO   17.19 (+0.00%)
BABA   80.38 (+3.22%)
AMD   68.52 (+2.01%)
T   15.83 (+0.64%)
MU   50.56 (-0.04%)
CGC   3.00 (+4.90%)
F   12.12 (+1.76%)
GE   64.77 (+0.47%)
DIS   98.76 (+3.04%)
AMC   7.58 (+1.74%)
PYPL   89.01 (+3.80%)
PFE   44.45 (+0.82%)
NFLX   240.32 (+7.11%)
S&P 500   3,706.77 (+1.63%)
DOW   29,582.77 (+1.54%)
QQQ   277.85 (+1.23%)
AAPL   147.18 (-3.02%)
MSFT   239.77 (+1.42%)
META   139.66 (+3.91%)
GOOGL   99.63 (+2.18%)
AMZN   116.93 (+2.20%)
TSLA   283.05 (+0.04%)
NVDA   127.24 (+2.51%)
NIO   17.19 (+0.00%)
BABA   80.38 (+3.22%)
AMD   68.52 (+2.01%)
T   15.83 (+0.64%)
MU   50.56 (-0.04%)
CGC   3.00 (+4.90%)
F   12.12 (+1.76%)
GE   64.77 (+0.47%)
DIS   98.76 (+3.04%)
AMC   7.58 (+1.74%)
PYPL   89.01 (+3.80%)
PFE   44.45 (+0.82%)
NFLX   240.32 (+7.11%)
NASDAQ:ZLAB

Zai Lab - ZLAB Stock Forecast, Price & News

$38.81
-0.03 (-0.08%)
(As of 09/28/2022 12:10 PM ET)
Add
Compare
Today's Range
$36.43
$39.08
50-Day Range
$37.00
$51.69
52-Week Range
$22.51
$112.16
Volume
3,876 shs
Average Volume
747,438 shs
Market Capitalization
$3.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.00

Zai Lab MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
218.2% Upside
$119.00 Price Target
Short Interest
Bearish
3.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.64mentions of Zai Lab in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.63) to ($4.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

930th out of 1,071 stocks

Pharmaceutical Preparations Industry

449th out of 531 stocks

ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

A Chinese pharma plans fast expansion of Cambridge HQ
Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
ZLAB Zai Lab Limited
Zai Lab Ltd
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Zai Lab Ltd ADR Repr 1 Shs
Why Earnings Season Could Be Great for Zai Lab (ZLAB)
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings
8/09/2022
Today
9/28/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
1,951
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$119.00
High Stock Price Forecast
$199.00
Low Stock Price Forecast
$64.00
Forecasted Upside/Downside
+206.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-704,470,000.00
Net Margins
-290.14%
Pretax Margin
-289.55%

Debt

Sales & Book Value

Annual Sales
$144.31 million
Book Value
$14.31 per share

Miscellaneous

Free Float
92,495,000
Market Cap
$3.80 billion
Optionable
Optionable
Beta
1.00

Key Executives

  • Dr. Ying Du Ph.D. (Age 56)
    Founder, Chairperson & CEO
    Comp: $1.64M
  • Mr. Ki Chul Cho (Age 44)
    Chief Financial Officer
    Comp: $720.97k
  • Mr. Frazor Titus Edmondson III (Age 56)
    Chief Legal Officer & Corp. Sec.
    Comp: $829k
  • Dr. Harald  Reinhart M.D.Dr. Harald Reinhart M.D. (Age 70)
    Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
    Comp: $845.94k
  • Dr. Alan Bart Sandler M.D. (Age 65)
    Pres & Head of Global Devel. in Oncology
    Comp: $1.19M
  • Mr. Joshua L. Smiley (Age 52)
    Chief Operating Officer
  • Ms. Ann E. Beasley J.D.
    Chief Compliance Officer
  • Ms. Danielle Halstrom
    Sr. VP & Global Head of Communications
  • Dr. Ning Xu M.D. (Age 57)
    Exec. VP & Head of Clinical Operations
  • Dr. Jonathan J. Wang M.B.A. (Age 40)
    MBA, Ph.D., Chief Bus. Officer













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2022?

5 Wall Street analysts have issued 1 year price targets for Zai Lab's stock. Their ZLAB share price forecasts range from $64.00 to $199.00. On average, they expect the company's stock price to reach $119.00 in the next year. This suggests a possible upside of 205.8% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2022?

Zai Lab's stock was trading at $62.85 at the start of the year. Since then, ZLAB shares have decreased by 38.1% and is now trading at $38.92.
View the best growth stocks for 2022 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.95) by $0.49. The business had revenue of $48.18 million for the quarter, compared to analyst estimates of $46.78 million. Zai Lab had a negative net margin of 290.14% and a negative trailing twelve-month return on equity of 38.53%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (3.48%), Credit Suisse AG (3.11%), Segantii Capital Management Ltd (2.29%), Genesis Investment Management LLP (1.64%), Price T Rowe Associates Inc. MD (1.50%) and State Street Corp (1.49%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $38.92.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.81 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($5.55) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 1,951 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.